Scholarlink

Background <p>New therapeutic strategies are needed to treat tuberculosis (TB). The antimicrobial peptide PK34 has a good ability to clear <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) and is not prone to drug resistance and adverse reactions. Mesenchymal stem cells (MSCs) can also be used as an adjunctive therapy for the treatment of TB. However, there have been no studies combining the two for the treatment of <i>Mtb</i> infection.</p> Methods <p>We aimed to construct bone-derived mesenchymal stem cells secreting the antimicrobial peptide PK34 (named Plent-PK34-BMSCs) and to investigate their roles in both in vitro and in vivo <i>Mtb</i> H37Rv infection models.</p> Results <p>We successfully constructed Plent-PK34-BMSCs that secrete and express the antimicrobial peptide PK34, and demonstrated that PK34 modified MSCs significantly enhanced their in vitro and in vivo antibacterial ability and cytoprotective effects. The cytokine results showed that Plent-PK34-BMSCs increased the levels of anti-inflammatory factors IL-4 and IL-10 in the cell supernatant, decreased the levels of pro-inflammatory factors IL-6 in the serum of the mice. In addition, lung tissue analysis results showed that mice treated with Plent-PK34-BMSCs had reduced infiltration and congestion of inflammatory cells in lung tissue, significantly reduced lung injury, and exhibited better preservation of lung structure.</p> Conclusions <p>PK34 modification enhanced the therapeutic efficacy of MSCs in <i>Mtb</i> infection models, and Plent-PK34-BMSCs transplantation has the potential to treat TB.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antimicrobial peptide PK34 modification enhances the antibacterial and anti-inflammatory effects of bone-derived mesenchymal stem cells in Mycobacterium tuberculosis infection

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月29日

查看全文
  • Xin-Yu He,
  • Jia-Qi Wang,
  • Yao Chen,
  • Ting-Xun Yuan,
  • Xiang Zhao,
  • Yi-Jing Sun,
  • Yi-Ming Liu,
  • Zhong-Yan Wang,
  • Yan-Bing Cai,
  • Wei Gao,
  • Chun-Ping Cui,
  • Zheng-Jun Yi,
  • Qian Li

摘要

Background

New therapeutic strategies are needed to treat tuberculosis (TB). The antimicrobial peptide PK34 has a good ability to clear Mycobacterium tuberculosis (Mtb) and is not prone to drug resistance and adverse reactions. Mesenchymal stem cells (MSCs) can also be used as an adjunctive therapy for the treatment of TB. However, there have been no studies combining the two for the treatment of Mtb infection.

Methods

We aimed to construct bone-derived mesenchymal stem cells secreting the antimicrobial peptide PK34 (named Plent-PK34-BMSCs) and to investigate their roles in both in vitro and in vivo Mtb H37Rv infection models.

Results

We successfully constructed Plent-PK34-BMSCs that secrete and express the antimicrobial peptide PK34, and demonstrated that PK34 modified MSCs significantly enhanced their in vitro and in vivo antibacterial ability and cytoprotective effects. The cytokine results showed that Plent-PK34-BMSCs increased the levels of anti-inflammatory factors IL-4 and IL-10 in the cell supernatant, decreased the levels of pro-inflammatory factors IL-6 in the serum of the mice. In addition, lung tissue analysis results showed that mice treated with Plent-PK34-BMSCs had reduced infiltration and congestion of inflammatory cells in lung tissue, significantly reduced lung injury, and exhibited better preservation of lung structure.

Conclusions

PK34 modification enhanced the therapeutic efficacy of MSCs in Mtb infection models, and Plent-PK34-BMSCs transplantation has the potential to treat TB.